{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T22:09:54Z","timestamp":1767650994196},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2005,3,24]],"date-time":"2005-03-24T00:00:00Z","timestamp":1111622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2005,3,24]],"date-time":"2005-03-24T00:00:00Z","timestamp":1111622400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Background<\/jats:title>\n                        <jats:p>Parkinson's disease (PD) is a chronic neurodegenerative disease which at present has no cure, and it usually results in severe disability. The burden of PD increases as the illness progresses, resulting in the extensive utilisation of both health and community services. Knowledge of healthcare use patterns and of their determinants may greatly contribute to improve patient care, however few studies have examined this issue in PD. The present study was devised to describe the type of and reasons for medical healthcare resource use in persons with PD attending a Centre for PD and Movement Disorders, and to examine drug prescriptions issued on such occasions.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>The study was a retrospective, cross-sectional survey in a cohort of ambulatory patients with PD, conducted by means of standard interviews.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>In the year before the study, 92 (70.8%) of 130 patients used medical healthcare resources: 1\/5 of the patients was admitted to hospital, 1\/5 to emergency room, 2\/5 were visited by a non-neurology specialist, and 1\/4 by the GP. Reasons were: nearly 20% programmed hospital admissions and visits, and more than 25% injuries and musculo-skeletal diseases. Other conditions typically occurring in PD (e.g. dementia, diabetes and cardio- and cerebro-vascular disease) were less frequently involved. On such occasions, drugs for PD were occasionally changed, however drug prescriptions for other indications were issued to more than 66% of the patients.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusion<\/jats:title>\n                        <jats:p>Several physicians other than the neurologist may take care of PD patients on different occasions, thus emphasising the need for communication between the reference neurologist and other physicians who from time to time may visit the patient.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/1472-6963-5-26","type":"journal-article","created":{"date-parts":[[2005,3,26]],"date-time":"2005-03-26T07:16:10Z","timestamp":1111821370000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Medical healthcare use in Parkinson's disease: survey in a cohort of ambulatory patients in Italy"],"prefix":"10.1186","volume":"5","author":[{"given":"Marco","family":"Cosentino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilia","family":"Martignoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donatella","family":"Michielotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Calandrella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulio","family":"Riboldazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Pacchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianmario","family":"Frigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Nappi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Lecchini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,3,24]]},"reference":[{"issue":"Suppl 5","key":"125_CR1","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1212\/WNL.56.suppl_5.S1","volume":"56","author":"CW Olanow","year":"2001","unstructured":"Olanow CW, Watts RL, Koller WC: An algorithm for the management of Parkinson's disease: treatment guidelines. Neurology. 2001, 56 (Suppl 5): S1-S88.","journal-title":"Neurology"},{"issue":"Suppl 4","key":"125_CR2","first-page":"S1","volume":"17","author":"CG Goetz","year":"2002","unstructured":"Goetz CG, Koller WC, Poewe W, et al: Management of Parkinson's disease: an evidence-based review. Mov Disord. 2002, 17 (Suppl 4): S1-S166.","journal-title":"Mov Disord"},{"issue":"Suppl 3","key":"125_CR3","first-page":"S157","volume":"24","author":"B Bergamasco","year":"2003","unstructured":"Bergamasco B, Abbruzzese G, Albanese A, et al: Guidelines for the treatment of Parkinson's Disease 2002. Neurol Sci. 2003, 24 (Suppl 3): S157-S164.","journal-title":"Neurol Sci"},{"key":"125_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1136\/jnnp.62.1.10","volume":"62","author":"MC de Rijk","year":"1997","unstructured":"de Rijk MC, Tzourio C, Breteler MM, et al: Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997, 62: 10-15.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"125_CR5","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1002\/1531-8257(200009)15:5<819::AID-MDS1009>3.0.CO;2-P","volume":"15","author":"JH Bower","year":"2000","unstructured":"Bower JH, Maraganore DM, McDonnell SK, Rocca WA: Influence of strict, intermediate, and broad diagnostic criteria on the age- and sex-specific incidence of Parkinson's disease. Mov Disord. 2000, 15: 819-825. 10.1002\/1531-8257(200009)15:5<819::AID-MDS1009>3.0.CO;2-P.","journal-title":"Mov Disord"},{"key":"125_CR6","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/0021-9681(73)90105-7","volume":"26","author":"E Singer","year":"1973","unstructured":"Singer E: Social costs of Parkinson's disease. J Chronic Dis. 1973, 26: 243-254. 10.1016\/0021-9681(73)90105-7.","journal-title":"J Chronic Dis"},{"key":"125_CR7","doi-asserted-by":"publisher","first-page":"486","DOI":"10.2165\/00019053-199712040-00006","volume":"12","author":"LM Rubinstein","year":"1997","unstructured":"Rubinstein LM, Chrischilles EA, Voelker MD: The impact of Parkinson's disease on health status, health expenditures, and productivity. Estimates from the National Medical Expenditure Survey. Pharmacoeconomics. 1997, 12: 486-498.","journal-title":"Pharmacoeconomics"},{"key":"125_CR8","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/S0025-6196(11)62259-3","volume":"77","author":"SA Parashos","year":"2002","unstructured":"Parashos SA, Maraganore DM, O'Brien PC, Rocca WA: Medical services utilization and prognosis in Parkinson's disease: a population-based study. Mayo Clin Proc. 2002, 77: 918-925.","journal-title":"Mayo Clin Proc"},{"key":"125_CR9","doi-asserted-by":"publisher","first-page":"A374","DOI":"10.1212\/WNL.50.2.374","volume":"50","author":"SK Van den Eeeden","year":"1998","unstructured":"Van den Eeeden SK, Nelson LM, Tanner CM: First year resource utilization among Parkinson's disease patients and matched controls in a managed care setting. Neurology. 1998, 50: A374.","journal-title":"Neurology"},{"key":"125_CR10","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/mds.10262","volume":"17","author":"P Hagell","year":"2002","unstructured":"Hagell P, Nordling S, Reimer J, Grabowski M, Persson U: Resource use and costs in a Swedish cohort of patients with Parkinson's disease. Mov Disord. 2002, 17: 1213-1220. 10.1002\/mds.10262.","journal-title":"Mov Disord"},{"key":"125_CR11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1212\/WNL.60.1.87","volume":"60","author":"JC Pressley","year":"2003","unstructured":"Pressley JC, Louis ED, Tang M-X, Cote L, Cohen PD, Glied S, Mayeux R: The impact of comorbid disease and injuries on resource use and expenditures in parkinsonism. Neurology. 2003, 60: 87-93. 10.1159\/000074508.","journal-title":"Neurology"},{"key":"125_CR12","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.2165\/00019053-200119100-00004","volume":"19","author":"RC Dodel","year":"2001","unstructured":"Dodel RC, Berger K, Oertel WH: Health related quality of life and healthcare utilisation in patients with Parkinson's disease. Impact of motor fluctuations and dyskinesias. Pharmacoeconomics. 2001, 19: 1013-1038.","journal-title":"Pharmacoeconomics"},{"key":"125_CR13","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/1531-8257(199909)14:5<772::AID-MDS1009>3.0.CO;2-S","volume":"14","author":"AGEM de Boer","year":"1999","unstructured":"de Boer AGEM, Sprangers MAG, Speelman HD, de Haes HCJM: Predictors of health care use in patients with Parkinson's disease: a longitudinal study. Mov Disord. 1999, 14: 772-779. 10.1002\/1531-8257(199909)14:5<772::AID-MDS1009>3.0.CO;2-S.","journal-title":"Mov Disord"},{"key":"125_CR14","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/pds.682","volume":"11","author":"O Leoni","year":"2002","unstructured":"Leoni O, Martignoni E, Cosentino M, et al: Drug prescribing patterns in Parkinson's disease: a pharmacoepidemiological survey in a cohort of ambulatory patients. Pharmacoepidemiol Drug Safety. 2002, 11: 149-157. 10.1002\/pds.682.","journal-title":"Pharmacoepidemiol Drug Safety"},{"key":"125_CR15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2165\/00019053-199916010-00006","volume":"16","author":"C Le Pen","year":"1999","unstructured":"Le Pen C, Wait S, Moutard-Martin F, et al: Cost of illness and disease severity in a cohort of French patients with Parkinson's disease. Pharmacoeconomics. 1999, 16: 59-69.","journal-title":"Pharmacoeconomics"},{"key":"125_CR16","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes AJ, Daniel SE, Kilford L, et al: The accuracy of the clinical diagnosis of Parkinson's disease: a clinicopathologic study of 100 cases. J Neurol Neurosurg Psychiatry. 1992, 55: 181-184.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"125_CR17","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1212\/WNL.17.5.427","volume":"17","author":"MH Hoehn","year":"1967","unstructured":"Hoehn MH, Yahr MD: Parkinsonism: onset, progression and mortality. Neurology. 1967, 17: 427-442.","journal-title":"Neurology"},{"key":"125_CR18","volume-title":"International Classification of Diseases","author":"Anonymous","year":"1997","unstructured":"Anonymous: International Classification of Diseases. 1997, Geneva: WHO, 9","edition":"9"},{"key":"125_CR19","volume-title":"Guidelines for ATC Classification","author":"Anonymous","year":"1993","unstructured":"Anonymous: Guidelines for ATC Classification. 1993, Oslo: WHO Collaborating Centre for Drug Statistics Methodology and Nordic Council on Medicines"},{"key":"125_CR20","first-page":"348","volume":"5","author":"M Ziegler","year":"1990","unstructured":"Ziegler M, Levy E: A cost analysis of the treatment of Parkinson disease. Ann Psychiatr. 1990, 5: 348-353.","journal-title":"Ann Psychiatr"},{"key":"125_CR21","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/mds.870130306","volume":"13","author":"EA Chrischilles","year":"1998","unstructured":"Chrischilles EA, Rubenstein LM, Voelker MD, Wallace RB, Rodnitzky RL: The health burdens of Parkinson's disease. Mov Disord. 1998, 13: 406-413.","journal-title":"Mov Disord"},{"key":"125_CR22","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2165\/00019053-199814030-00006","volume":"14","author":"RC Dodel","year":"1998","unstructured":"Dodel RC, Singer M, K\u00f6hne-Volland R, et al: The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis. Pharmacoeconomics. 1998, 14: 299-312.","journal-title":"Pharmacoeconomics"},{"key":"125_CR23","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1136\/jnnp.72.6.721","volume":"72","author":"BH Wood","year":"2002","unstructured":"Wood BH, Bilclough JA, Bowron A, Walker RW: Incidence and prediction of falls in Parkinson's disease: a prospective multidisciplinary study. J Neurol Neurosurg Psychiatry. 2002, 72: 721-725. 10.1136\/jnnp.72.6.721.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"125_CR24","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1001\/archneur.60.4.529","volume":"60","author":"NJ Diederich","year":"2003","unstructured":"Diederich NJ, Moore CG, Leurgans SE, et al: Parkinson disease with old-age onset. A comparative study with subjects with middle-age onset. Arch Neurol. 2003, 60: 529-533. 10.1001\/archneur.60.4.529.","journal-title":"Arch Neurol"},{"key":"125_CR25","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1002\/mds.10527","volume":"18","author":"A Schrag","year":"2003","unstructured":"Schrag A, Hovris A, Morley D, et al: Young versus older-onset Parkinson's disease: impact of disease and psychosocial consequences. Mov Disord. 2003, 18: 1250-1256. 10.1002\/mds.10527.","journal-title":"Mov Disord"},{"key":"125_CR26","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1345\/aph.1A226","volume":"36","author":"A Kennerfalk","year":"2002","unstructured":"Kennerfalk A, Ruig\u00f2mez A, Wallander MA, et al: Geriatric drug therapy and healthcare utilization in the United Kingdom. Ann Pharmacother. 2002, 36: 797-803. 10.1345\/aph.1A226.","journal-title":"Ann Pharmacother"},{"key":"125_CR27","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1002\/1531-8257(200005)15:3<490::AID-MDS1011>3.0.CO;2-E","volume":"15","author":"HH Fernandez","year":"2000","unstructured":"Fernandez HH, Lapane KL, Ott BR, Friedman JH: Gender differences in the frequency and treatment of behavior problems in Parkinson's disease. Mov Disord. 2000, 15: 490-496. 10.1002\/1531-8257(200005)15:3<490::AID-MDS1011>3.0.CO;2-E.","journal-title":"Mov Disord"},{"key":"125_CR28","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11920-002-0016-7","volume":"4","author":"TA Zeiewicz","year":"2002","unstructured":"Zeiewicz TA, Hauser RA: Depression in Parkinson's disease. Curr Psychiatry Rep. 2002, 4: 69-73.","journal-title":"Curr Psychiatry Rep"},{"key":"125_CR29","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/S0090-4295(00)00641-5","volume":"56","author":"GE Lemack","year":"2000","unstructured":"Lemack GE, Dewey RB, Roehrborn CG, et al: Questionnaire-based assessment of bladder dysfunction in patients with mild to moderate Parkinson's disease. Urology. 2000, 56: 250-254. 10.1016\/S0090-4295(00)00641-5.","journal-title":"Urology"},{"key":"125_CR30","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1016\/S0140-6736(02)11668-0","volume":"360","author":"CE Clarke","year":"2002","unstructured":"Clarke CE, Guttmann M: Dopamine agonist monotherapy in Parkinson's disease. Lancet. 2002, 360: 1767-1769. 10.1016\/S0140-6736(02)11668-0.","journal-title":"Lancet"},{"issue":"suppl 4","key":"125_CR31","first-page":"IV\/17","volume":"247","author":"H Reichmann","year":"2000","unstructured":"Reichmann H: Long-term treatment with dopamine agonists in idiopathic Parkinson's disease. J Neurol. 2000, 247 (suppl 4): IV\/17-IV\/19.","journal-title":"J Neurol"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6963-5-26.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/1472-6963-5-26\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6963-5-26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6963-5-26.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T12:32:09Z","timestamp":1728304329000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/1472-6963-5-26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3,24]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2005,12]]}},"alternative-id":["125"],"URL":"https:\/\/doi.org\/10.1186\/1472-6963-5-26","relation":{},"ISSN":["1472-6963"],"issn-type":[{"type":"electronic","value":"1472-6963"}],"subject":[],"published":{"date-parts":[[2005,3,24]]},"assertion":[{"value":"3 November 2004","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2005","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2005","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"26"}}